Effect of Renal and Left Ventricular Function on Serial Pulmonary Arterial Pressure Changes after Device Closure of Atrial Septal Defect
Table 4
Comparison between patients with increased PASP and decreased PASP immediately after device closure of ASDs.
Variable
PASP decrease (n = 55)
PASP increase (n = 21)
value
Age, years
47.7 ± 14.4
56.4 ± 15.2
0.022
Female, n (%)
36 (66)
14 (67)
0.921
Body surface area, m2
1.62 ± 0.14
1.57 ± 0.18
0.288
Body mass index, kg/m2
22.3 ± 2.9
22.3 ± 3.1
0.986
Systolic blood pressure, mmHg
116.7 ± 13.7
115.1 ± 19.7
0.027
Atrial fibrillation, n (%)
4 (7)
2 (10)
0.745
Blood urea nitrogen, mg/dL
14.4 ± 3.7
16.7 ± 5.8
0.046
Creatinine, mg/dL
0.74 ± 0.15
0.80 ± 0.20
0.168
eGFR, mL/min/1.73 m²
102.6 ± 17.4
91.3 ± 20.3
0.018
Maximal defect diameter, mm
20.1 ± 6.2
21.1 ± 5.7
0.522
Defect area, mm2
253.0 ± 144.1
263.5 ± 156.4
0.794
Device diameter, mm
23.6 ± 6.5
25.0 ± 5.9
0.411
Qp/Qs ratio
2.46 ± 0.82
2.79 ± 0.95
0.214
LV mass index, g/m2
62.6 ± 14.1
64.4 ± 21.3
0.673
LA volume index, mL/m2
29.0 ± 12.5
35.4 ± 11.7
0.046
LV ejection fraction, %
67.4 ± 5.9
63.4 ± 7.0
0.015
Stroke volume, mL
52.4 ± 11.2
51.9 ± 11.7
0.869
TRV, m/sec
2.83 ± 0.46
2.48 ± 0.45
0.004
PASP, mmHg
39.2 ± 12.7
31.6 ± 9.6
0.016
PVR, Wood unit
1.49 ± 0.27
1.42 ± 0.42
0.425
e’, cm/s
9.8 ± 3.0
7.7 ± 3.4
0.013
E/e’
8.65 ± 3.29
10.10 ± 3.94
0.120
Amplatzer, Abbott/Cocoon, Vascular Innovations/Figulla Flex II, Occlutech/Helex, Gore
29/23/3/0
10/10/0/1
0.266
In two patients, pre- or post-TRV were not measurable. ASD, atrial septal defect; e’, early diastolic septal mitral annular velocity; E/e’, ratio of early mitral inflow velocity to e’; eGFR, estimated glomerular filtration rate; LA, left atrial; LV, left ventricular; PASP, pulmonary arterial systolic pressure; PVR, pulmonary vascular resistance; TRV, tricuspid regurgitant velocity.
